139 related articles for article (PubMed ID: 8602879)
1. Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase.
Barham HM; Stratford IJ
Biochem Pharmacol; 1996 Mar; 51(6):829-37. PubMed ID: 8602879
[TBL] [Abstract][Full Text] [Related]
2. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver.
Walton MI; Wolf CR; Workman P
Biochem Pharmacol; 1992 Jul; 44(2):251-9. PubMed ID: 1642640
[TBL] [Abstract][Full Text] [Related]
3. Application of hepatic cytochrome b
Reed L; Indra R; Mrizova I; Moserova M; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
Toxicol Appl Pharmacol; 2019 Mar; 366():64-74. PubMed ID: 30685480
[TBL] [Abstract][Full Text] [Related]
4. Vanadate-dependent NAD(P)H oxidation by microsomal enzymes.
Reif DW; Coulombe RA; Aust SD
Arch Biochem Biophys; 1989 Apr; 270(1):137-43. PubMed ID: 2494940
[TBL] [Abstract][Full Text] [Related]
5. One-electron reductive bioactivation of 2,3,5,6-tetramethylbenzoquinone by cytochrome P450.
Goeptar AR; te Koppele JM; van Maanen JM; Zoetemelk CE; Vermeulen NP
Biochem Pharmacol; 1992 Jan; 43(2):343-52. PubMed ID: 1310854
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a spectrophotometric assay for measuring the activity of NADH: cytochrome b5 reductase in human tumour cells.
Barham HM; Inglis R; Chinje EC; Stratford IJ
Br J Cancer; 1996 Oct; 74(8):1188-93. PubMed ID: 8883403
[TBL] [Abstract][Full Text] [Related]
7. Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075).
Riley RJ; Hemingway SA; Graham MA; Workman P
Biochem Pharmacol; 1993 Mar; 45(5):1065-77. PubMed ID: 8461036
[TBL] [Abstract][Full Text] [Related]
8. Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes.
Yamazaki H; Nakano M; Gillam EM; Bell LC; Guengerich FP; Shimada T
Biochem Pharmacol; 1996 Jul; 52(2):301-9. PubMed ID: 8694855
[TBL] [Abstract][Full Text] [Related]
9. Electron-transport cytochrome P-450 system is involved in the microsomal metabolism of the carcinogen chromate.
Garcia JD; Jennette KW
J Inorg Biochem; 1981 Jul; 14(4):281-95. PubMed ID: 6792322
[TBL] [Abstract][Full Text] [Related]
10. Regulative mechanisms in NADH- and NADPH-supported N-oxidation of 4-chloroaniline catalyzed by cytochrome b5-enriched rabbit liver microsomal fractions.
Golly I; Hlavica P
Biochim Biophys Acta; 1987 Jun; 913(2):219-27. PubMed ID: 3109485
[TBL] [Abstract][Full Text] [Related]
11. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9.
Plumb JA; Gerritsen M; Workman P
Br J Cancer; 1994 Dec; 70(6):1136-43. PubMed ID: 7526885
[TBL] [Abstract][Full Text] [Related]
12. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes.
Yamazaki H; Nakano M; Imai Y; Ueng YF; Guengerich FP; Shimada T
Arch Biochem Biophys; 1996 Jan; 325(2):174-82. PubMed ID: 8561495
[TBL] [Abstract][Full Text] [Related]
13. Selective induction of cytochrome b5 and NADH cytochrome b5 reductase by propylthiouracil.
Kariya K; Lee E; Yamaoka M; Ishikawa H
Life Sci; 1984 Dec; 35(23):2327-34. PubMed ID: 6438427
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of bioreductive activation of anticancer drugs idarubicin and mitomycin C by NADH-cytochrome b5 reductase and cytochrome P450 2B4.
Celik H; Arinç E
Xenobiotica; 2013 Mar; 43(3):263-75. PubMed ID: 22928801
[TBL] [Abstract][Full Text] [Related]
15. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin.
Walton MI; Workman P
Biochem Pharmacol; 1990 Jun; 39(11):1735-42. PubMed ID: 2344370
[TBL] [Abstract][Full Text] [Related]
16. Reductive activation of mitomycin C by NADH:cytochrome b5 reductase.
Hodnick WF; Sartorelli AC
Cancer Res; 1993 Oct; 53(20):4907-12. PubMed ID: 8402680
[TBL] [Abstract][Full Text] [Related]
17. Effect of divalent cations on NADH-dependent and NADPH-dependent cytochrome b5 reduction by hepatic microsomes.
Tamura M; Yoshida S; Tamura T; Saitoh T; Takeshita M
Arch Biochem Biophys; 1990 Aug; 280(2):313-9. PubMed ID: 2369123
[TBL] [Abstract][Full Text] [Related]
18. Evidence for a predominantly NADH-dependent O-dealkylating system in rat hepatic microsomes.
Kuwahara S; Mannering GJ
Biochem Pharmacol; 1985 Dec; 34(24):4215-28. PubMed ID: 3935115
[TBL] [Abstract][Full Text] [Related]
19. The opposite effect of bivalent cations on cytochrome b5 reduction by NADH:cytochrome b5 reductase and NADPH:cytochrome c reductase.
Tamura M; Yubisui T; Takeshita M
Biochem J; 1988 May; 251(3):711-5. PubMed ID: 3137923
[TBL] [Abstract][Full Text] [Related]
20. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.
Keyes SR; Fracasso PM; Heimbrook DC; Rockwell S; Sligar SG; Sartorelli AC
Cancer Res; 1984 Dec; 44(12 Pt 1):5638-43. PubMed ID: 6437671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
